DK1569696T3 - Fremgangsmåder og immunmodulatoriske nukleinsyrepræparater til forebyggelse og behandling af sygdomme - Google Patents

Fremgangsmåder og immunmodulatoriske nukleinsyrepræparater til forebyggelse og behandling af sygdomme

Info

Publication number
DK1569696T3
DK1569696T3 DK03789883.0T DK03789883T DK1569696T3 DK 1569696 T3 DK1569696 T3 DK 1569696T3 DK 03789883 T DK03789883 T DK 03789883T DK 1569696 T3 DK1569696 T3 DK 1569696T3
Authority
DK
Denmark
Prior art keywords
methods
prevention
treatment
diseases
relates
Prior art date
Application number
DK03789883.0T
Other languages
English (en)
Inventor
Hideki Garren
Peggy P Ho
Lawrence Steinman
Original Assignee
Bayhill Therapeutics Inc
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayhill Therapeutics Inc, Univ Leland Stanford Junior filed Critical Bayhill Therapeutics Inc
Application granted granted Critical
Publication of DK1569696T3 publication Critical patent/DK1569696T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK03789883.0T 2002-11-21 2003-11-21 Fremgangsmåder og immunmodulatoriske nukleinsyrepræparater til forebyggelse og behandling af sygdomme DK1569696T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42864302P 2002-11-21 2002-11-21
PCT/US2003/037157 WO2004047734A2 (en) 2002-11-21 2003-11-21 Methods and immune modulatory nucleic acid compositions for preventing and treating disease

Publications (1)

Publication Number Publication Date
DK1569696T3 true DK1569696T3 (da) 2010-11-15

Family

ID=32393438

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03789883.0T DK1569696T3 (da) 2002-11-21 2003-11-21 Fremgangsmåder og immunmodulatoriske nukleinsyrepræparater til forebyggelse og behandling af sygdomme

Country Status (15)

Country Link
US (1) US7811813B2 (da)
EP (5) EP1569696B1 (da)
JP (2) JP4750419B2 (da)
CN (2) CN100546657C (da)
AT (1) ATE477000T1 (da)
AU (2) AU2003294400B2 (da)
CA (1) CA2507249A1 (da)
DE (1) DE60333786D1 (da)
DK (1) DK1569696T3 (da)
ES (1) ES2350576T3 (da)
IL (1) IL168715A (da)
NZ (1) NZ540276A (da)
PT (1) PT1569696E (da)
SI (1) SI1569696T1 (da)
WO (1) WO2004047734A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2326848T3 (es) * 1997-06-06 2009-10-20 The Regents Of The University Of California Inhibidores de la actividad de secuencias inmunoestimulatorias de adn.
DK1794174T3 (da) * 2004-09-01 2012-07-09 Dynavax Tech Corp Fremgangsmåder og sammensætninger til hæmning af medfødte immunresponser og autoimmunitet
WO2006136821A1 (en) * 2005-06-22 2006-12-28 Astex Therapeutics Limited Pharmaceutical compounds
US20100130593A1 (en) * 2006-06-13 2010-05-27 Bayhill Therapeutics, Inc. Methods and immune modulator nucleic acid compositions for preventing and treating disease
EP2712930A3 (en) * 2006-12-06 2014-04-23 MedImmune, LLC Interferon alpha-induced pharmacodynamic markers
US20100261172A1 (en) * 2007-05-03 2010-10-14 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
EP2068924A4 (en) 2007-05-03 2011-07-20 Medimmune Llc INTERFERON ALPHA INDUCED PHARMACODYNAMIC MARKERS
WO2009055076A2 (en) 2007-10-26 2009-04-30 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
AU2010229835B2 (en) 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
EA201291357A1 (ru) 2010-06-16 2013-11-29 Дайнэвокс Текнолоджиз Корпорейшн Способы лечения с применением ингибиторов tlr7 и/или tlr9
SE535625C2 (sv) 2010-10-28 2012-10-16 Toleranzia Ab Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
US20130236453A1 (en) * 2012-03-12 2013-09-12 The Ohio State University Methods and Compositions for Modulating Acute Graft-versus-Host Disease using miR-155 Specific Inhibitors
WO2013160865A1 (en) 2012-04-26 2013-10-31 Toleranzia Ab Immunotolerizing fusion proteins for treatment of multiple sclerosis
US9228184B2 (en) * 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
US9868955B2 (en) 2012-09-29 2018-01-16 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
BR112019007408A2 (pt) 2016-11-01 2019-07-02 Novo Nordisk As vacina de dna tolerogênica
US11279745B2 (en) 2019-04-26 2022-03-22 Novo Nordisk A/S Tolerogenic DNA vaccine

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4425732A (en) 1981-06-17 1984-01-17 Kania Tadeusz E Animal trap
US4650675A (en) 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5218103A (en) 1988-05-26 1993-06-08 University Patents, Inc. Nucleoside thiophosphoramidites
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69535905D1 (de) * 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
US5712258A (en) 1995-03-23 1998-01-27 The Trustees Of The University Of Pennsylvania Inotropic ADP and ATP analogues and their pharmaceutical compositions
US5939400A (en) 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
WO1997046253A2 (en) 1996-06-03 1997-12-11 Powderject Vaccines, Inc. Immunotherapy for autoimmune disease
ATE292980T1 (de) * 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
ES2326848T3 (es) * 1997-06-06 2009-10-20 The Regents Of The University Of California Inhibidores de la actividad de secuencias inmunoestimulatorias de adn.
US6087341A (en) 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
US7030098B2 (en) * 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
AU2001229472A1 (en) * 2000-01-10 2001-07-24 Elim Biopharmaceuticals, Inc. Novel plasmid dna vectors
EP1985702A3 (en) * 2000-12-08 2010-08-18 Coley Pharmaceutical GmbH CPG-like nucleic acids and methods of use thereof
CA2435758C (en) * 2001-11-21 2016-08-02 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy against autoantigens for treating insulin dependent diabetes mellitus
US20050002953A1 (en) * 2003-05-06 2005-01-06 Jens Herold SARS-coronavirus virus-like particles and methods of use
CA2540890A1 (en) * 2003-10-03 2005-04-14 Bayhill Therapeutics, Inc. Treatment of demyelinating autoimmune disease with modified ordered peptides
WO2007147011A2 (en) * 2006-06-13 2007-12-21 Bayhill Therapeutics, Inc. Polynucleotide therapy
JP2009544703A (ja) * 2006-07-24 2009-12-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法
WO2009099642A2 (en) * 2008-02-05 2009-08-13 The Board Of Trustees Of The Leland Stanford Junior University Proteomic analysis of active multiple sclerosis lesions

Also Published As

Publication number Publication date
NZ540276A (en) 2007-12-21
EP2322186A3 (en) 2011-07-13
ATE477000T1 (de) 2010-08-15
EP1569696A2 (en) 2005-09-07
AU2003294400B2 (en) 2008-12-18
EP2329827A3 (en) 2011-07-13
CN100546657C (zh) 2009-10-07
EP2298360A3 (en) 2011-07-13
AU2003294400A1 (en) 2004-06-18
ES2350576T3 (es) 2011-01-25
EP2322186A2 (en) 2011-05-18
WO2004047734A3 (en) 2004-08-12
CN101955976A (zh) 2011-01-26
EP2353614A1 (en) 2011-08-10
PT1569696E (pt) 2010-11-11
IL168715A (en) 2011-09-27
JP4750419B2 (ja) 2011-08-17
DE60333786D1 (de) 2010-09-23
EP2298360A2 (en) 2011-03-23
JP2011148801A (ja) 2011-08-04
JP2006514933A (ja) 2006-05-18
EP1569696B1 (en) 2010-08-11
EP1569696A4 (en) 2006-01-11
EP2329827A2 (en) 2011-06-08
SI1569696T1 (sl) 2010-12-31
AU2009201102A1 (en) 2009-04-09
US20050261215A1 (en) 2005-11-24
WO2004047734A2 (en) 2004-06-10
US7811813B2 (en) 2010-10-12
CN1777447A (zh) 2006-05-24
CA2507249A1 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
DK1569696T3 (da) Fremgangsmåder og immunmodulatoriske nukleinsyrepræparater til forebyggelse og behandling af sygdomme
CY1110353T1 (el) Ανοσορρυθμιστικοι ολιγοσακχαριτες
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2003045316A3 (en) Polynucleotide therapy
WO2005002526A3 (en) Method and compositions for treatment of viral infections
IL169367A0 (en) Defensin proteins
WO2007147007A3 (en) Methods and immune modulatory nucleic acid compositions for preventing and treating disease
MXPA03000979A (es) Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
IL169256A0 (en) Metalloprotease proteins
BR0014167A (pt) Proteìna iren, sua preparação e aplicação
DK1449535T3 (da) Præparater der omfatter fötalt hæmoglobin og bakterieendotoksin samt eventuelt fötale leverbestanddele
NO20052525D0 (no) Spleisevariant av humant hypofyseveksthormon
WO2005005471A3 (en) Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2004101618A3 (en) Progestin-yol002c-cgi-45 receptor-related proteins
WO2003054178A3 (en) Metalloprotease proteins
WO2004035626A8 (en) Alpha macroglobulin protein family members
WO2004026905A3 (en) Transporter/channel proteins
EA200400534A1 (ru) Стимуляция тимозином генетической иммунизации
MXPA05012414A (es) Proteina secretada similar a tnf.
WO2002044382A8 (en) Cytokine-like proteins
WO2004056863A3 (en) Splice variant of human placental growth hormone
WO2005049063A3 (en) Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2003100061A3 (en) Three finger toxin fold proteins
WO2005014029A3 (en) Use of dg008, dg065, dg210 or dg 239 secreted protein products for preventing and treating pancreatic diseases, obesity or metabolic syndrome
WO2002029062A3 (en) Cytokine proteins